The China small molecule CDMO market is expected to reach USD 46.0 billion by 2030, registering a CAGR of 19.4% from 2023 to 2030. Low cost associated with outsourcing services in China, a high number of China-based CDMOs offering end to end contract development & manufacturing organization (CDMO) services and surge in the geriatric population in the country contributing to the disease burden in the country is further supporting the demand for CDMO services in China.
China is recognized across the world as one of the largest industrial hubs. Moreover, it is among the world's most affordable manufacturing destinations. Compared to the products made in the U.S., those made in China cost 5% less, and products built or assembled in Europe cost a staggering 10%-20% higher. China has much lower labor expenses than Western nations. Chinese workers are paid USD 11.90 per hour, whereas in the U.S. workers are paid USD 35.96 per hour. All these factors support the CDMO market in China.
In January 2022, China signed the Asia Pacific free trade agreement. As per this agreement, countries such as Brunei Darussalam, Australia, China, Cambodia, Japan, the Republic of Korea, Indonesia, Laos, Myanmar, New Zealand, Malaysia, Singapore, the Philippines, Thailand, and Viet Nam will enjoy free trade, which means 90% of trade tariffs will be eliminated if these countries trade among themselves. This is expected to improve the outsourcing activities of drug development and manufacturing in China from these countries in the coming years and thus support market growth.
The WHO states that, in the coming years, the geriatric population of China is expected to rise. In 2019, there were 176 million individuals aged 65 years or older, and by 2040, 402 million people will be over the age of 60, which represents around 28% of the world's population. The rise in the aging population is expected to increase the demand for pharmaceutical contract development & manufacturing activities in the country during the post-pandemic period.
China is recognized across the world as one of the largest industrial hubs. Moreover, it is among the world's most affordable manufacturing destinations. Compared to the products made in the U.S., those made in China cost 5% less, and products built or assembled in Europe cost a staggering 10%-20% higher. China has much lower labor expenses than Western nations. Chinese workers are paid USD 11.90 per hour, whereas in the U.S. workers are paid USD 35.96 per hour. All these factors support the CDMO market in China.
In January 2022, China signed the Asia Pacific free trade agreement. As per this agreement, countries such as Brunei Darussalam, Australia, China, Cambodia, Japan, the Republic of Korea, Indonesia, Laos, Myanmar, New Zealand, Malaysia, Singapore, the Philippines, Thailand, and Viet Nam will enjoy free trade, which means 90% of trade tariffs will be eliminated if these countries trade among themselves. This is expected to improve the outsourcing activities of drug development and manufacturing in China from these countries in the coming years and thus support market growth.
The WHO states that, in the coming years, the geriatric population of China is expected to rise. In 2019, there were 176 million individuals aged 65 years or older, and by 2040, 402 million people will be over the age of 60, which represents around 28% of the world's population. The rise in the aging population is expected to increase the demand for pharmaceutical contract development & manufacturing activities in the country during the post-pandemic period.
China Small Molecule CDMO Market Report Highlights
- The API segment dominated the China small molecule contract development & manufacturing organization market with the largest revenue share of 61.8% in 2022. This is due the4 high dependence on China for API and increase in the API exports from China
- Based on synthesis, the synthetic segment held the largest share of 73.2% in 2022, this is due to the increase in small molecule CDMO activities in China
- Based on drug, the generic segment is expected to expand at the fastest rate of 19.8%CAGR, owing to the initiatives taken by the government to improve access of generics in the country. A significant number of drugs going off patent are further supporting the segment market
- Based on workflow, the commercial segment held the largest share of 53.1% in 2022 due to the high number of commercial drug manufacturing activities conducted in the country
- Based on application, oncology segment held the largest share of 38.6% in 2022. Owing to a significant number of drug manufacturing and development activities conducted in the oncology segment in the country
Table of Contents
Chapter 1. Methodology and Scope1.1. Market Segmentation & Scope
1.1.1. Product
1.1.2. Synthesis
1.1.3. Drug
1.1.4. Workflow
1.1.5. Application
1.1.6. Regional scope
1.1.7. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.6.1. Commodity flow analysis (Model 1)
1.6.2. Volume price analysis (Model 2)
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
1.9.1. Objective 1
1.9.2. Objective 2
1.9.3. Objective 3
1.9.4. Objective 4
Chapter 2. Executive Summary
2.1. Market Outlook
Chapter 3. China Small Molecule CDMO Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Market Dynamics
3.3.1. Market driver analysis
3.3.1.1. Increase in depend for one-stop-shops CDMOs.
3.3.1.2. Low cost associated with outsourcing services in China.
3.3.1.3. High geriatric population contributing to the growing diseases burden in China.
3.3.2. Market restraint analysis
3.3.2.1. Quality issues associated with outsourcing.
3.3.2.2. Limited outsourcing opted by big pharma companies
3.3.3. Covid-19 Impact & Recovery Analysis
3.3.4. Industry Analysis - Porter’s
3.3.5. PESTLE Analysis
3.3.6. Regulatory Scenario in China
Chapter 4. China Small Molecule CDMO Market: Product Segment Analysis
4.1. China Small Molecule CDMO Market : Definition & Scope
4.2. China Small Molecule CDMO Market : Product Market Share Analysis, 2022 & 2030
4.3. Active Pharmaceutical Ingredients (API)
4.3.1. Active Pharmaceutical Ingredients (API) Market, 2018 - 2030 (USD Million)
4.3.2. Innovator API Market, 2018 - 2030 (USD Million)
4.3.2.1. Innovator API Market, 2018 - 2030 (USD Million)
4.3.2.2. Traditional Active Pharmaceutical Ingredient (Traditional API)
4.3.2.2.1. Traditional Active Pharmaceutical Ingredient (Traditional API) Market, 2018 - 2030 (USD Million)
4.3.2.3. Highly Potent Active Pharmaceutical Ingredient (HP-API)
4.3.2.3.1. Highly Potent Active Pharmaceutical Ingredient (HP-API) Market, 2018 - 2030 (USD Million)
4.3.2.4. Antibody Drug Conjugate (ADC)
4.3.2.4.1. Antibody Drug Conjugate (ADC) Market, 2018 - 2030 (USD Million)
4.3.3. Generic API Market, 2018 - 2030 (USD Million)
4.3.3.1. Innovator API Market, 2018 - 2030 (USD Million)
4.3.3.2. Traditional Active Pharmaceutical Ingredient (Traditional API)
4.3.3.2.1. Traditional Active Pharmaceutical Ingredient (Traditional API) Market, 2018 - 2030 (USD Million)
4.3.3.3. Highly Potent Active Pharmaceutical Ingredient (HP-API)
4.3.3.3.1. Highly Potent Active Pharmaceutical Ingredient (HP-API) Market, 2018 - 2030 (USD Million)
4.3.3.4. Antibody Drug Conjugate (ADC)
4.3.3.4.1. Antibody Drug Conjugate (ADC) Market, 2018 - 2030 (USD Million)
Chapter 5. China Small Molecule CDMO Market: Synthesis Segment Analysis
5.1. China Small Molecule CDMO Market: Definition & Scope
5.2. China Small Molecule CDMO Market: Synthesis Market Share Analysis, 2022 & 2030
5.3. Synthetic
5.3.1. Synthetic Market, 2018 - 2030 (USD Million)
5.4. Biotech
5.4.1. Biotech Market, 2018 - 2030 (USD Million)
Chapter 6. China Small Molecule CDMO Market: Drug Segment Analysis
6.1. China Small Molecule CDMO Market: Definition & Scope
6.2. China Small Molecule CDMO Market: Drug Market Share Analysis, 2022 & 2030
6.3. Innovative
6.3.1. Innovative Market, 2018 - 2030 (USD Million)
6.4. Generic
6.4.1. Generic Market, 2018 - 2030 (USD Million)
Chapter 7. China Small Molecule CDMO Market: Workflow Segment Analysis
7.1. China Small Molecule CDMO Market: Definition & Scope
7.2. China Small Molecule CDMO Market: Workflow Market Share Analysis, 2022 & 2030
7.3. Clinical
7.3.1. Clinical Market, 2018 - 2030 (USD Million)
7.4. Commercial
7.4.1. Commercial Market, 2018 - 2030 (USD Million)
Chapter 8. China Small Molecule CDMO Market: Application Segment Analysis
8.1. China Small Molecule CDMO Market: Definition & Scope
8.2. China Small Molecule CDMO Market: Application Market Share Analysis, 2022 & 2030
8.3. Oncology
8.3.1. Oncology Market, 2018 - 2030 (USD Million)
8.4. Hormonal
8.4.1. Hormonal Market, 2018 - 2030 (USD Million)
8.5. Glaucoma
8.5.1. Glaucoma Market, 2018 - 2030 (USD Million)
8.6. Cardiovascular
8.6.1. Cardiovascular Market, 2018 - 2030 (USD Million)
8.7. Diabetes
8.7.1. Diabetes Market, 2018 - 2030 (USD Million)
8.8. Others
8.8.1. Others Market, 2018 - 2030 (USD Million)
Chapter 9. Competitive Landscape
9.1. Market Share Analysis
9.2. Participant Categorization
9.2.1. Recent Development and Impact Analysis
Chapter 10. Company Profiles
10.1. Company Overview
10.2. Financial Performance
10.3. Strategic Initiatives
10.3.1. Expansions
10.3.2. Partnerships and Collaborations
10.3.3. Acquisitions
10.3.3.1. Bellen Chemistry
10.3.3.2. Zhejiang LangHua Pharmaceutical Co., LTD.
10.3.3.3. Raffles PharmaTech Co., Ltd
10.3.3.4. Shanghai Mathcon Pharmaceutical Co., LTD
10.3.3.5. Wisdom Pharmaceutical Co., Ltd.
10.3.3.6. Gear Pharma
10.3.3.7. Hangzhou Aoya Biotechnology Co., Ltd.
10.3.3.8. Desano Inc.
10.3.3.9. Shanghai Chemspec Corporation
10.3.3.10. Zhejiang Chetou Pharmaceutical Co., Ltd
List of Tables
Table 1 List of secondary sources
Table 2 List of Abbreviations
List of Figures
Fig. 1 Market research process
Fig. 2 Information Procurement
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value chain based sizing & forecasting
Fig. 6 QFD modelling for market share assessment
Fig. 7 Market segmentation & scope
Fig. 8 China small molecule CDMO market outlook, 2018 - 2030
Fig. 9 Market trends & outlook
Fig. 10 Market driver relevance analysis (Current & future impact)
Fig. 11 Market restraint relevance analysis (Current & future impact)
Fig. 12 SWOT Analysis, By Factor (political & legal, economic and technological)
Fig. 13 Porter’s Five Forces Analysis
Fig. 14 China small molecule CDMO market : Product outlook key takeaways
Fig. 15 China small molecule CDMO market : Product movement analysis
Fig. 16 Active Pharmaceutical Ingredients (API) market, 2018 - 2030 (USD Million)
Fig. 17 Innovator API market, 2018 - 2030 (USD Million)
Fig. 18 Traditional Active Pharmaceutical Ingredients market, 2018 - 2030 (USD Million)
Fig. 19 Highly Potent Active Pharmaceutical Ingredients (HP-API) market, 2018 - 2030
Fig. 20 Antibody Drug Conjugates (ADCs) market, 2018 - 2030 (USD Million)
Fig. 21 Generic API market, 2018 - 2030 (USD Million)
Fig. 22 Traditional Active Pharmaceutical Ingredients market, 2018 - 2030 (USD Million)
Fig. 23 Highly Potent Active Pharmaceutical Ingredients (HP-API) market, 2018 - 2030
Fig. 24 Antibody Drug Conjugates (ADCs) market, 2018 - 2030 (USD Million)
Fig. 25 Finished Drug Products market, 2018 - 2030 (USD Million)
Fig. 26 Solid market, 2018 - 2030 (USD Million)
Fig. 27 Injectable market, 2018 - 2030 (USD Million)
Fig. 28 Others market, 2018 - 2030 (USD Million)
Fig. 29 China small molecule CDMO market: Synthesis outlook key takeaways
Fig. 30 China small molecule CDMO market: Synthesis movement analysis
Fig. 31 Synthetic market, 2018 - 2030 (USD Million)
Fig. 32 Biotech market, 2018 - 2030 (USD Million)
Fig. 33 China small molecule CDMO market: Drug outlook key takeaways
Fig. 34 China small molecule CDMO market : Drug movement analysis
Fig. 35 Innovative market, 2018 - 2030 (USD Million)
Fig. 36 Generic market, 2018 - 2030 (USD Million)
Fig. 37 China small molecule CDMO market :Work Flow outlook key takeaways
Fig. 38 China small molecule CDMO market : Work Flow movement analysis
Fig. 39 Clinical market, 2018 - 2030 (USD Million)
Fig. 40 Commercial market, 2018 - 2030 (USD Million)
Fig. 41 China small molecule CDMO market :Application outlook key takeaways
Fig. 42 China small molecule CDMO market : Application movement analysis
Fig. 43 Oncology market, 2018 - 2030 (USD Million)
Fig. 44 Hormonal market, 2018 - 2030 (USD Million)
Fig. 45 Glaucoma market, 2018 - 2030 (USD Million)
Fig. 46 Cardiovascular market, 2018 - 2030 (USD Million)
Fig. 47 Diabetes market, 2018 - 2030 (USD Million)
Fig. 48 Others market, 2018 - 2030 (USD Million)
Companies Mentioned
- Bellen Chemistry
- Zhejiang LangHua Pharmaceutical Co., LTD.
- Raffles PharmaTech Co., Ltd
- Shanghai Mathcon Pharmaceutical Co., LTD
- Wisdom Pharmaceutical Co., Ltd.
- Gear Pharma
- Hangzhou Aoya Biotechnology Co., Ltd.
- Desano Inc.
- Shanghai Chemspec Corporation
- Zhejiang Chetou Pharmaceutical Co., Ltd
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 100 |
| Published | February 2023 |
| Forecast Period | 2022 - 2030 |
| Estimated Market Value ( USD | $ 11 Billion |
| Forecasted Market Value ( USD | $ 46 Billion |
| Compound Annual Growth Rate | 19.4% |
| Regions Covered | China |
| No. of Companies Mentioned | 10 |
